NCT04684680 is a NA clinical trial of zamzam water in Oligohydramnios, sponsored by Aswan University Hospital.

Who is sponsoring NCT04684680?

NCT04684680 is sponsored by Aswan University Hospital.

What drugs are being tested in NCT04684680?

Interventions in NCT04684680: zamzam water, tap water.

What condition does NCT04684680 study?

NCT04684680 studies Oligohydramnios.

Is NCT04684680 still recruiting?

NCT04684680 is currently status unknown. Last updated 9 August 2021.

Last reviewed 2021-08-09 · How we verify

NCT04684680

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Role of Zamzam Water in Idiopathic Oligohydramnios

Status unknown NA Last updated 9 August 2021

What this trial tests

NA trial testing zamzam water in Oligohydramnios in 120 participants. Status unknown.

Timeline

1 January 2021

Primary endpoint
30 September 2021

1 November 2021

Quick facts

Lead sponsor	Aswan University Hospital
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	120
Start date	1 January 2021
Primary completion	30 September 2021
Estimated completion	1 November 2021
Sites	1 location across Egypt

Drugs / interventions tested

zamzam water
tap water — full drug profile →

Conditions studied

Oligohydramnios — all drugs for Oligohydramnios →

Sponsor

Aswan University Hospital

Who can join

Adults 18 to 40, female only, with Oligohydramnios. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this study is to evaluate the efficacy of drinking zamzam water versus tap water in increasing the AF index in women with oligohydramnios.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Oligohydramnios

Currently open trials in the same condition.

NCT07135037 — Comparison Between Treatments of Oligohydramnios · Phase 2 · recruiting
NCT05043753 — "Fetal gRowth AbnorMality dEtection Trial" · NA · recruiting
NCT04451109 — Dilapan-S®: A Multicenter US E-registry · active not recruiting

Other Aswan University Hospital trials

Trials by the same sponsor.

NCT06491394 — Lactoferrin Effect on Kidney and Heart of Rhabdomyolysis Rats · Phase 4 · completed
NCT06211088 — Famotidine Versus Placebo in Emergency Pediatric Surgery As a Risk to Postoperative Nausea and Vomiting · NA · completed
NCT06583590 — Evaluation of Efficacy of Botulinum Toxin A Plus Oral Tadalafil 5 mg in Diabetic Men With Erectile Dysfunction · Phase 2, PHASE3 · recruiting
NCT06537323 — Femoral Nerve Block, Periarticular Nerve Group (PENG) Block, and Preoperative IV Fentanyl · NA · recruiting
NCT06535256 — Compare Intraperitoneal Instillation of Bupivacaine+dexmedetomidine Versus Bupivacaine+dexamethasone on Postoperative Pa · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04684680 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Aswan University Hospital
Last refreshed: 9 August 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04684680.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing